Frontiers in Bioengineering and Biotechnology (Jul 2022)
Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study
- Stéphane Odet,
- Christophe Meyer,
- Christophe Meyer,
- Camille Gaudet,
- Elise Weber,
- Julie Quenot,
- Stéphane Derruau,
- Stéphane Derruau,
- Sebastien Laurence,
- Sebastien Laurence,
- Lisa Bompy,
- Marine Girodon,
- Brice Chatelain,
- Cédric Mauprivez,
- Cédric Mauprivez,
- Cédric Mauprivez,
- Esteban Brenet,
- Halima Kerdjoudj,
- Halima Kerdjoudj,
- Narcisse Zwetyenga,
- Philippe Marchetti,
- Philippe Marchetti,
- Anne-Sophie Hatzfeld,
- Anne-Sophie Hatzfeld,
- David Toubeau,
- Fabienne Pouthier,
- Fabienne Pouthier,
- Xavier Lafarge,
- Xavier Lafarge,
- Heinz Redl,
- Heinz Redl,
- Mathilde Fenelon,
- Mathilde Fenelon,
- Jean-Christophe Fricain,
- Jean-Christophe Fricain,
- Roberta Di Pietro,
- Roberta Di Pietro,
- Charlotte Ledouble,
- Charlotte Ledouble,
- Charlotte Ledouble,
- Thomas Gualdi,
- Anne-Laure Parmentier,
- Aurélien Louvrier,
- Aurélien Louvrier,
- Florelle Gindraux,
- Florelle Gindraux
Affiliations
- Stéphane Odet
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Christophe Meyer
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Christophe Meyer
- Laboratoire de Nanomédecine, Imagerie, Thérapeutique EA 4662, Université Bourgogne Franche-Comté, Besançon, France
- Camille Gaudet
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Elise Weber
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Julie Quenot
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Stéphane Derruau
- Pôle Médecine bucco-dentaire, Hôpital Maison Blanche, CHU Reims, Reims, France
- Stéphane Derruau
- Université de Reims Champagne-Ardenne, Laboratoire BioSpecT EA-7506, UFR de Pharmacie, Reims, France
- Sebastien Laurence
- Pôle Médecine bucco-dentaire, Hôpital Maison Blanche, CHU Reims, Reims, France
- Sebastien Laurence
- Université de Reims Champagne Ardenne, Biomatériaux et Inflammation en Site Osseux, Pôle Santé, URCA, HERVI EA3801, UFR de Médecine, Reims, France
- Lisa Bompy
- Chirurgie Maxillo-Faciale - Stomatologie - Chirurgie Plastique Réparatrice et Esthétique - Chirurgie de la main, CHU de Dijon, Dijon, France
- Marine Girodon
- Chirurgie Maxillo-Faciale - Stomatologie - Chirurgie Plastique Réparatrice et Esthétique - Chirurgie de la main, CHU de Dijon, Dijon, France
- Brice Chatelain
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Cédric Mauprivez
- Pôle Médecine bucco-dentaire, Hôpital Maison Blanche, CHU Reims, Reims, France
- Cédric Mauprivez
- Université de Reims Champagne Ardenne, Biomatériaux et Inflammation en Site Osseux, Pôle Santé, URCA, BIOS EA 4691, Reims, France
- Cédric Mauprivez
- UFR d’Odontologie, Université de Reims Champagne Ardenne, Reims, France
- Esteban Brenet
- Service d’ORL et chirurgie cervico-faciale, CHU Reims, Reims, France
- Halima Kerdjoudj
- Université de Reims Champagne Ardenne, Biomatériaux et Inflammation en Site Osseux, Pôle Santé, URCA, BIOS EA 4691, Reims, France
- Halima Kerdjoudj
- UFR d’Odontologie, Université de Reims Champagne Ardenne, Reims, France
- Narcisse Zwetyenga
- Chirurgie Maxillo-Faciale - Stomatologie - Chirurgie Plastique Réparatrice et Esthétique - Chirurgie de la main, CHU de Dijon, Dijon, France
- Philippe Marchetti
- 0Banque de Tissus CBP CHU Lille, Lille, France
- Philippe Marchetti
- 1Institut de Cancérologie ONCOLILLE CANTHER, UMR9020 CNRS–U1277 Inserm—Université de Lille, Lille, France
- Anne-Sophie Hatzfeld
- 0Banque de Tissus CBP CHU Lille, Lille, France
- Anne-Sophie Hatzfeld
- 1Institut de Cancérologie ONCOLILLE CANTHER, UMR9020 CNRS–U1277 Inserm—Université de Lille, Lille, France
- David Toubeau
- 2Banque de Tissus, CHU Rouen, Rouen, France
- Fabienne Pouthier
- 3Activité d’Ingénierie Cellulaire et Tissulaire (AICT), Établissement Français du Sang Bourgogne Franche-Comté, Besançon, France
- Fabienne Pouthier
- 4Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
- Xavier Lafarge
- 5Établissement Français du Sang Nouvelle-Aquitaine, Bordeaux, France
- Xavier Lafarge
- 6INSERM U1035, Université de Bordeaux, Biothérapie des Maladies Génétiques Inflammatoires et Cancers (BMGIC), Bordeaux, France
- Heinz Redl
- 7Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA, Research Center, Vienna, Austria
- Heinz Redl
- 8Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Mathilde Fenelon
- 9Univ. Bordeaux, INSERM, BIOTIS, U1026, Bordeaux, France
- Mathilde Fenelon
- 0CHU Bordeaux, Service de chirurgie orale, Bordeaux, France
- Jean-Christophe Fricain
- 9Univ. Bordeaux, INSERM, BIOTIS, U1026, Bordeaux, France
- Jean-Christophe Fricain
- 0CHU Bordeaux, Service de chirurgie orale, Bordeaux, France
- Roberta Di Pietro
- 1Department of Medicine and Ageing Sciences, Gabriele D’Annunzio University of Chieti-Pescara, Chieti, Italy
- Roberta Di Pietro
- 2StemTeCh Group, Gabriele D’Annunzio Foundation, University of Chieti-Pescara, Chieti, Italy
- Charlotte Ledouble
- Pôle Médecine bucco-dentaire, Hôpital Maison Blanche, CHU Reims, Reims, France
- Charlotte Ledouble
- Université de Reims Champagne Ardenne, Biomatériaux et Inflammation en Site Osseux, Pôle Santé, URCA, BIOS EA 4691, Reims, France
- Charlotte Ledouble
- UFR d’Odontologie, Université de Reims Champagne Ardenne, Reims, France
- Thomas Gualdi
- 3Inserm CIC 1431, CHU Besançon, Besançon, France
- Anne-Laure Parmentier
- 3Inserm CIC 1431, CHU Besançon, Besançon, France
- Aurélien Louvrier
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Aurélien Louvrier
- 4Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France
- Florelle Gindraux
- Service de chirurgie maxillo-faciale, stomatologie et odontologie hospitalière, CHU Besançon, Besançon, France
- Florelle Gindraux
- Laboratoire de Nanomédecine, Imagerie, Thérapeutique EA 4662, Université Bourgogne Franche-Comté, Besançon, France
- DOI
- https://doi.org/10.3389/fbioe.2022.936074
- Journal volume & issue
-
Vol. 10
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors. There are currently no guidelines on its management, particularly in advanced stages. The human amniotic membrane (hAM) has low immunogenicity and exerts anti-inflammatory, antifibrotic, antimicrobial, antiviral, and analgesic effects. It is a source of stem cells and growth factors promoting tissue regeneration. hAM acts as an anatomical barrier with suitable mechanical properties (permeability, stability, elasticity, flexibility, and resorbability) to prevent the proliferation of fibrous tissue and promote early neovascularization at the surgical site. In oral surgery, hAM stimulates healing and facilitates the proliferation and differentiation of epithelial cells in the oral mucosa and therefore its regeneration. We proposed using cryopreserved hAM to eight patients suffering from cancer (11 lesions) with stage 2–3 MRONJ on a compassionate use basis. A collagen sponge was added in some cases to facilitate hAM grafting. One or three hAMs were applied and one patient had a reapplication. Three patients had complete closure of the surgical site with proper epithelialization at 2 weeks, and two of them maintained it until the last follow-up. At 1 week after surgery, three patients had partial wound dehiscence with partial healing 3 months later and two patients had complete wound dehiscence. hAM reapplication led to complete healing. All patients remained asymptomatic with excellent immediate significant pain relief, no infections, and a truly positive impact on the patients’ quality of life. No adverse events occurred. At 6 months of follow-up, 80% of lesions had complete or partial wound healing (30 and 50%, respectively), while 62.5% of patients were in stage 3. Radiological evaluations found that 85.7% of patients had stable bone lesions (n = 5) or new bone formation (n = 1). One patient had a worsening MRONJ but remained asymptomatic. One patient did not attend his follow-up radiological examination. For the first time, this prospective pilot study extensively illustrates both the handling and surgical application of hAM in MRONJ, its possible association with a collagen sponge scaffold, its outcome at the site, the application of multiple hAM patches at the same time, and its reapplication.
Keywords